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Eﬀ ect of physical inactivity on major non-communicable 
diseases worldwide: an analysis of burden of disease and 
life expectancy
I-Min Lee, Eric J Shiroma, Felipe Lobelo, Pekka Puska, Steven N Blair, Peter T Katzmarzyk, for the Lancet Physical Activity Series Working Group*
Summary
Background Strong evidence shows that physical inactivity increases the risk of many adverse health conditions, 
including major non-communicable diseases such as coronary heart disease, type 2 diabetes, and breast and colon 
cancers, and shortens life expectancy. Because much of the world’s population is inactive, this link presents a major 
public health issue. We aimed to quantify the eﬀ ect of physical inactivity on these major non-communicable diseases 
by estimating how much disease could be averted if inactive people were to become active and to estimate gain in life 
expectancy at the population level.
Methods For our analysis of burden of disease, we calculated population attributable fractions (PAFs) associated with 
physical inactivity using conservative assumptions for each of the major non-communicable diseases, by country, to 
estimate how much disease could be averted if physical inactivity were eliminated. We used life-table analysis to 
estimate gains in life expectancy of the population.
Findings Worldwide, we estimate that physical inactivity causes 6% (ranging from 3·2% in southeast Asia to 7·8% in 
the eastern Mediterranean region) of the burden of disease from coronary heart disease, 7% (3·9–9·6) of type 2 
diabetes, 10% (5·6–14·1) of breast cancer, and 10% (5·7–13·8) of colon cancer. Inactivity causes 9% (range 5·1–12·5) 
of premature mortality, or more than 5·3 million of the 57 million deaths that occurred worldwide in 2008. If inactivity 
were not eliminated, but decreased instead by 10% or 25%, more than 533 000 and more than 1·3 million deaths, 
respectively, could be averted every year. We estimated that elimination of physical inactivity would increase the life 
expectancy of the world’s population by 0·68 (range 0·41–0·95) years.
Interpretation Physical inactivity has a major health eﬀ ect worldwide. Decrease in or removal of this unhealthy 
behaviour could improve health substantially. 
Funding None.
Introduction
Ancient physicians—including those from China in 
2600 BC and Hippocrates around 400 BC—believed in 
the value of physical activity for health. By the 20th 
century, however, a diametrically opposite view—that 
exercise was dangerous—prevailed instead.1 During the 
early 20th century, complete bed rest was prescribed for 
patients with acute myocardial infarction. And, at the 
time of the 100th boat race between the Universities of 
Oxford and Cambridge, UK, in 1954, the senior health 
oﬃ  cer of Cambridge University undertook a study to 
investigate the alleged dangers of exercise by comparing 
university sportsmen with intellectuals.1
One of the pioneers whose work helped to change that 
tide of popular opinion was Jerry Morris, who undertook 
the ﬁ rst rigorous, epidemiological studies investigating 
physical inactivity and chronic disease risk, published in 
1953.2 Since then, much evidence has clearly documented 
the many health beneﬁ ts of physical activity (panel 1).3–5 
Despite this knowledge, a large proportion of the world’s 
population remains physically inactive. To quantify the 
eﬀ ect of physical inactivity on the world’s major non-
communicable diseases, we estimated how much of 
these diseases could be averted in the population if 
inactive people were to become active, as well as how 
much gain in life expectancy could occur at the 
population level. We focus on the major non-com-
municable diseases emphasised by the UN as threats to 
global health:6 coronary heart disease; cancer, speciﬁ cally 
breast and colon cancers, which are convincingly related 
to physical inactivity; and type 2 diabetes.
Methods
Population attributable fraction
The population attributable fraction (PAF) is a measure 
used by epidemiologists to estimate the eﬀ ect of a risk 
factor on disease incidence in a population.7,8 It estimates 
the proportion of new cases that would not occur, absent 
a particular risk factor. Thus, it provides policy makers 
with useful quantitative estimates of the potential eﬀ ect 
of interventions to reduce or eradicate the risk factor.
PAF is related to prevalence of the risk factor and its 
associated relative risk (RR). At least two formulae are 
available to calculate PAF (panel 2). Formula 1 provides 
an unbiased estimate when there is no confounding of 
the relation between the risk factor and disease, and 
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requires knowledge of the prevalence of the risk factor in 
the population and the RR not to be adjusted for 
confounders (crude RR). Formula 2 is preferred when 
there is confounding;8 it requires knowledge of the 
prevalence of the risk factor in people eventually 
developing the disease (cases) and the adjusted RR. 
Because some confounders (eg, hypertension in coronary 
heart disease, overweight in diabetes) are exacerbated by 
inactivity, formula 2 might overadjust, whereas formula 1 
can add perspective. Thus, we sought prevalence 
estimates of inactivity for the whole population and 
unadjusted RRs to estimate PAF using formula 1, and 
prevalence estimates of inactivity for cases and adjusted 
RRs to estimate PAF using formula 2.
Estimation of prevalence of physical inactivity
We deﬁ ned physical inactivity to be an activity level 
insuﬃ  cient to meet present recommendations.5 WHO 
obtains data, by country, for the prevalence of physical 
inactivity in the population using two similar stand-
ardised questionnaires; the latest data are for 2008.9 For 
calculation of PAFs with RRs adjusted for confounding 
factors, the prevalence of physical inactivity at baseline in 
cases of the outcome of interest was needed. These data 
proved diﬃ  cult to obtain for countries outside North 
America and Europe. Further, data for prevalence of 
inactivity depended on the instrument used for assess-
ment and varied according to whether a study assessed 
physical activity during leisure only (most commonly), or 
also included activities in occupation, transportation, or 
home-based activities.
Thus, to estimate the prevalence of inactivity in cases, we 
contacted several large cohort studies throughout the 
world using input from the Lancet Physical Activity 
Series Working Group, attempting particularly to gather 
data outside North America and Europe. For each study, 
we obtained the prevalence of physical inactivity in 
all participants at baseline, and in those eventually 
developing coronary heart disease, type 2 diabetes, and 
breast and colon cancer and those who died (appendix). 
For each outcome, we calculated an adjustment factor, 
representing the added extent to which physical inactivity 
occurred in cases compared with the overall population of 
the cohort study. For example, in the Shanghai Women’s 
Health Study (appendix), the prevalence of inactivity in 
all women at baseline was 45·4% versus 51·6% in 
women who died, yielding an adjustment factor of 1·14 
(51·6 / 45·4 = 1·14). For each outcome, we calculated the 
adjustment factor in every study, and averaged this factor 
across studies. We applied the average adjustment factor to 
the prevalence of physical inactivity, by country, to estimate 
the prevalence of inactivity in cases of coronary heart 
disease, type 2 diabetes, breast and colon cancer, and death 
from any cause.
Estimation of RRs associated with physical inactivity
We searched electronic databases (Medline and Embase) 
using keywords related to physical activity (“physical 
activity”, “motor activity”, “energy expenditure”, “walk-
ing”, and “exercise”) and the outcomes of interest (“breast 
cancer”, “breast carcinoma”, “colon cancer”, “colorectal 
cancer”, “colon carcinoma”, “colorectal carcinoma”, 
“diabetes”, “type 2 diabetes”, “all-cause mortality”, 
“mortality”, “cardiovascular disease”, “coronary heart 
disease”, and “heart disease”) for peer-reviewed reviews 
of adults published in English, selecting the most recent 
one as of June 30, 2011. For all outcomes apart from 
breast cancer, published meta-analyses of the pooled RR 
were available.10–13 For breast cancer, no comprehensive 
See Online for appendix
Panel 1: Health beneﬁ ts of physical activity in adults3–5
Strong evidence of reduced rates of:
• All-cause mortality
• Coronary heart disease
• High blood pressure
• Stroke
• Metabolic syndrome
• Type 2 diabetes
• Breast cancer
• Colon cancer
• Depression
• Falling
Strong evidence of:
• Increased cardiorespiratory and muscular ﬁ tness
• Healthier body mass and composition
• Improved bone health
• Increased functional health
• Improved cognitive function
Panel 2: Formulae for calculation of population 
attributable fraction (PAF)
Formula 1, using unadjusted relative risk:
Where Pe is the proportion of inactive people in the source 
population, and RRunadj is the relative risk of disease, 
comparing inactive with active people, unadjusted for 
confounding factors.
Formula 2, using adjusted relative risk:
Where Pd is the proportion of inactive people among cases, 
and RRadj is the relative risk of disease, comparing inactive 
with active people, adjusted for confounding factors.
PAF(%)
Pd(RRadj – 1)=
RRadj
× 100
PAF(%)
Pe(RRunadj – 1)=
Pe(RRunadj – 1) + 1
× 100
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meta-analysis was found (one of only case-control studies 
is available14), so we selected the most recent qualitative 
review15 and did a meta-analysis of their primary studies.
All the meta-analyses calculated only pooled RRs 
adjusted for potential confounders (generally selecting 
maximally adjusted RRs from individual studies); no 
pooled estimates of crude RRs were reported. Thus, we 
obtained the primary papers to identify the crude RRs. 
For most papers, this information was not reported; for 
several, data were provided that allowed its calculation. 
When the crude RR was unavailable or could not be 
calculated, the age-adjusted RR was often available. 
Thus, to obtain a pooled estimate of the crude RRs, we 
used either crude RRs or age-adjusted RRs, calling this 
value the unadjusted RR. This method enabled use of 
data from a larger number of studies, and a closer 
parallel between studies used to calculate the pooled 
unadjusted and adjusted RRs. In sensitivity analyses 
that compared results using only crude RRs with those 
using both crude and age-adjusted RRs, estimates were 
generally similar; thus, bias using unadjusted instead of 
crude RRs is unlikely. We used simple, random-eﬀ ects 
meta-regres sion to account for heterogeneity across 
studies, using MIX 2.0.
Calculation of PAFs and gains in life expectancy
We calculated PAFs for each outcome, by country, and 
used Monte Carlo simulation techniques (10 000 simu-
lations) to estimate 95% CIs. We assumed normal dis-
tributions for physical inactivity prevalence and the log of 
the RRs. We used life-table analysis to estimate gains in 
life expectancy that could be expected if physical inactivity 
were eliminated, using life tables published by WHO 
that provide age-speciﬁ c death rates, by country; the 
latest data are for 2009.16
Since the country-speciﬁ c PAF for all-cause mortality 
estimates how much premature mortality can be 
removed from the population if physical inactivity were 
eliminated, we assumed that the age-speciﬁ c death rates 
for a country would be decreased by an amount equal to 
this PAF (calculated using the adjusted RR) if inactivity 
were eliminated. Studies of physical activity and all-cause 
mortality have mainly been in people aged 40 years and 
older, with few data available for those aged 80 years and 
older, which also suggest beneﬁ t.3 Thus, we con ser-
vatively decreased age-speciﬁ c death rates by the PAF 
only for ages 40–79 years, and calculated the revised life 
expectancy from birth, by country. In a sensitivity 
analysis, we did parallel analyses that decreased age-
speciﬁ c death rates for all ages 40 years and older.
Role of the funding source
No funding organisation had any role in the writing of 
the report or the decision to submit for publication. The 
corresponding author had full access to all data in the 
study and ﬁ nal responsibility for the decision to submit 
for publication.
Results
We estimated the prevalence of physical inactivity in 
cases of the outcomes studied, by country, using adjust-
ment factors of 1·20 (SE 0·03) for coronary heart disease, 
1·23 (0·05) for type 2 diabetes, 1·05 (0·09) for breast 
cancer, 1·22 (0·08) for colon cancer, and 1·22 (0·07) for 
all-cause mortality. The highest prevalence was noted in 
people who went on to develop type 2 diabetes, followed 
by those who died and those who developed colon 
cancer, coronary heart disease, and breast cancer (table 1, 
appendix). 
Table 1 sum marises the RRs associated with physical 
inactivity, unadjusted and adjusted for confounders, for 
the outcomes studied. Sattelmair and colleagues10 investi-
gated the dose-re sponse relation between leisure-time 
energy expenditure and incidence of coronary heart 
disease. The pooled RR associated with energy expen-
diture that fulﬁ lled present recommendations compared 
Coronary heart 
disease
Type 2 diabetes Breast cancer* Colon cancer All-cause mortality
Prevalence of inactivity in population (%)† 35·2% (22·3–40·5) 35·2% (22·3–40·5) 38·8% (23·3–44·3) 35·2% (22·3–40·5) 35·2% (22·3–40·5)
Prevalence of inactivity in people eventually 
developing the outcome (%)†
42·2% (23·0–56·2) 43·2% (23·6–57·6) 40·7% (22·5–56·7) 42·9% (23·4–57·1) 42·9% (23·4–57·1)
RR, unadjusted‡ 1·33 (1·18–1·49) 1·63 (1·27–2·11) 1·34 (1·25–1·43) 1·38 (1·31–1·45) 1·47 (1·38–1·57)
RR, adjusted‡ 1·16 (1·04–1·30) 1·20 (1·10–1·33) 1·33 (1·26–1·42) 1·32 (1·23–1·39) 1·28 (1·21–1·36)
PAF with unadjusted RR (%)§ 10·4% (7·2–13·4) 18·1% (10·8–22·8) 11·6% (6·8–15·5) 11·8% (6·8–15·1) 14·2% (8·3–18·0)
PAF with adjusted RR (%)§ 5·8% (3·2–7·8) 7·2% (3·9–9·6) 10·1% (5·6–14·1) 10·4% (5·7–13·8) 9·4% (5·1–12·5)
 Physical inactivity was deﬁ ned as insuﬃ  cient physical activity to meet present recommendations. RR=relative risk. PAF=population attributable fraction. *Women only. 
†Data are overall median (range of medians for WHO regions); details of country-speciﬁ c values for the population are available from reference 9; country-speciﬁ c values for 
people eventually developing these diseases are provided in the appendix. ‡Data are RR (95% CI); for details of calculation of unadjusted RRs, see appendix; the unadjusted 
RRs pooled both crude and age-adjusted RRs, since the crude RR was often unavailable; the adjusted RR of coronary heart disease was obtained from Sattelmair and 
colleagues,10 for type 2 diabetes from Jeon and colleagues,11 for breast cancer and all-cause mortality see appendix, and for colon cancer from Wolin and co-workers.12 §Data 
are overall median (range of medians for WHO regions); details of  country-speciﬁ c values calculated with unadjusted RRs are provided in appendix; country-speciﬁ c values 
calculated with adjusted RRs are shown in table 2.
Table 1: Summary of estimates of the prevalence of physical inactivity, RRs, and PAFs for coronary heart disease, type 2 diabetes, breast cancer, colon 
cancer, and all-cause mortality associated with physical inactivity
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Coronary heart disease Type 2 diabetes Breast cancer Colon cancer All-cause mortality
Africa
Algeria 6·7% (2·4 to 11·2) 8·3% (4·2 to 12·9) 12·8% (5·9 to 20·0) 12·0% (6·8 to 17·2) 10·8% (8·6 to 13·1)
Benin 1·5% (0·5 to 2·5) 1·9% (0·9 to 2·9) 2·9% (1·3 to 4·6) 2·7% (1·5 to 3·9) 2·4% (1·9 to 3·0)
Botswana 5·8% (2·1 to 9·7) 7·2% (3·6 to 11·3) 11·5% (5·4 to 18·0) 10·4% (5·9 to 15·1) 9·4% (7·5 to 11·4)
Burkina Faso 2·6% (–0·2 to 6·1) 3·2% (–0·3 to 7·2) 4·3% (–1·0 to 9·5) 4·6% (–0·8 to 9·9) 4·1% (–0·1 to 8·6)
Cameroon 6·7% (1·0 to 13·9) 8·3% (1·8 to 16·2) 12·6% (1·8 to 23·8) 12·0% (2·3 to 22·1) 10·9% (3·4 to 18·6)
Cape Verde 3·4% (1·3 to 5·7) 4·2% (2·1 to 6·6) 7·7% (3·5 to 11·8) 6·1% (3·4 to 8·9) 5·5% (4·3 to 6·8)
Chad 4·1% (0·0 to 9·3) 5·0% (–0·2 to 11·0) 6·8% (–0·8 to 14·4) 7·3% (–0·3 to 15·1) 6·5% (0·4 to 12·9)
Comoros 1·4% (–0·3 to 3·6) 1·7% (–0·4 to 4·2) 2·8% (–0·9 to 6·4) 2·5% (–0·8 to 5·7) 2·2% (–0·5 to 5·0)
Congo (Brazzaville) 8·0% (1·4 to 16·4) 10·0% (2·2 to 19·1) 13·8% (2·8 to 24·9) 14·4% (3·0 to 26·2) 13·0% (4·4 to 22·0)
Côte d’Ivoire 5·4% (0·6 to 11·9) 6·7% (0·8 to 13·9) 9·6% (0·7 to 19·0) 9·7% (0·7 to 18·5) 8·8% (2·0 to 16·1)
Democratic Republic of the Congo 7·5% (2·8 to 12·4) 9·3% (4·7 to 14·5) 13·6% (6·5 to 21·1) 13·4% (7·3 to 19·4) 12·1% (9·6 to 14·6)
Eritrea 6·7% (2·4 to 11·2) 8·3% (4·2 to 12·8) 14·3% (6·7 to 22·4) 12·0% (6·7 to 17·1) 10·8% (8·6 to 13·0)
Ethiopia 3·2% (–0·1 to 7·6) 4·0% (–0·1 to 8·9) 5·8% (–0·9 to 12·7) 5·7% (–0·6 to 12·1) 5·2% (0·2 to 10·5)
Gabon 6·1% (0·5 to 13·3) 7·5% (0·6 to 15·5) 12·1% (0·7 to 23·6) 10·8% (0·6 to 21·5) 9·8% (1·8 to 18·2)
Ghana 2·9% (1·1 to 4·8) 3·6% (1·8 to 5·7) 5·4% (2·5 to 8·4) 5·2% (2·9 to 7·5) 4·7% (3·7 to 5·7)
Guinea 2·0% (–0·2 to 5·0) 2·5% (–0·2 to 5·6) 4·7% (–0·7 to 10·2) 3·6% (–0·6 to 7·7) 3·2% (–0·1 to 6·7)
Kenya 2·7% (–0·4 to 6·8) 3·4% (–0·6 to 7·9) 4·7% (–1·1 to 10·6) 4·9% (–1·0 to 10·9) 4·4% (–0·3 to 9·3)
Madagascar 3·9% (1·4 to 6·4) 4·8% (2·4 to 7·5) 7·4% (3·5 to 11·5) 6·9% (3·9 to 10·0) 6·2% (4·9 to 7·5)
Malawi 1·7% (0·6 to 2·8) 2·1% (1·0 to 3·3) 3·4% (1·6 to 5·3) 3·0% (1·7 to 4·4) 2·7% (2·1 to 3·3)
Mali 3·5% (–0·1 to 8·0) 4·3% (–0·2 to 9·5) 6·2% (–0·7 to 13·4) 6·2% (–0·7 to 13·1) 5·6% (0·2 to 11·1)
Mauritania 7·3% (1·5 to 14·3) 9·0% (2·2 to 16·9) 12·4% (3·3 to 21·8) 13·0% (3·0 to 23·0) 11·7% (4·5 to 19·2)
Mauritius 6·4% (0·7 to 13·5) 7·9% (1·3 to 15·9) 10·2% (0·8 to 20·0) 11·4% (1·2 to 21·6) 10·3% (2·6 to 18·2)
Mozambique 1·2% (0·4 to 2·0) 1·5% (0·7 to 2·3) 1·9% (0·9 to 3·0) 2·1% (1·1 to 3·1) 1·9% (1·5 to 2·4)
Namibia 9·7% (2·3 to 18·9) 12·0% (3·5 to 22·2) 17·0% (4·6 to 29·5) 17·3% (5·0 to 29·9) 15·6% (7·0 to 24·8)
Niger 4·9% (1·8 to 8·0) 6·0% (3·0 to 9·3) 8·9% (4·2 to 14·1) 8·7% (4·8 to 12·6) 7·8% (6·2 to 9·5)
São Tomé and PrÍncipe 3·1% (1·1 to 5·2) 3·9% (2·0 to 6·0) 6·9% (3·1 to 10·6) 5·6% (3·1 to 8·2) 5·1% (4·0 to 6·2)
Senegal 3·8% (0·0 to 8·8) 4·7% (0·1 to 10·1) 6·7% (–0·7 to 14·2) 6·8% (–0·3 to 13·7) 6·2% (0·5 to 12·0)
Seychelles 3·7% (1·3 to 6·1) 4·6% (2·3 to 7·2) 5·8% (2·6 to 9·2) 6·6% (3·7 to 9·6) 6·0% (4·7 to 7·3)
Sierra Leone 3·3% (1·1 to 5·4) 4·1% (2·0 to 6·3) 6·2% (2·9 to 9·5) 5·9% (3·3 to 8·5) 5·3% (4·2 to 6·5)
South Africa 8·7% (3·1 to 14·5) 10·7% (5·4 to 16·8) 14·7% (6·7 to 23·1) 15·5% (8·8 to 22·4) 14·0% (11·1 to 16·9)
Swaziland 11·4% (3·2 to 21·5) 14·2% (4·7 to 25·1) 18·8% (5·9 to 32·4) 20·4% (7·3 to 33·7) 18·4% (9·4 to 27·7)
The Gambia 4·1% (1·5 to 6·7) 5·0% (2·5 to 7·8) 7·5% (3·5 to 11·7) 7·3% (4·1 to 10·5) 6·5% (5·2 to 7·9)
Zambia 2·9% (–0·3 to 7·0) 3·5% (–0·5 to 8·2) 5·0% (–1·2 to 11·3) 5·1% (–1·0 to 11·4) 4·6% (–0·2 to 9·6)
Zimbabwe 3·9% (0·0 to 9·0) 4·9% (–0·1 to 10·7) 6·7% (–0·8 to 14·3) 7·0% (–0·4 to 14·6) 6·4% (0·6 to 12·4)
Median for region 3·9% 4·8% 7·1% 7·0% 6·3%
Latin America and Caribbean
Argentina 11·3% (3·1 to 21·0) 14·0% (4·8 to 24·7) 18·5% (5·9 to 31·7) 20·2% (6·8 to 33·5) 18·2% (9·5 to 27·7)
Barbados 7·8% (2·8 to 13·0) 9·6% (4·8 to 15·0) 14·5% (6·8 to 22·7) 13·9% (7·6 to 20·1) 12·5% (9·9 to 15·1)
Brazil 8·2% (1·5 to 16·4) 10·1% (2·4 to 18·9) 13·4% (2·3 to 24·7) 14·6% (2·9 to 26·1) 13·2% (4·8 to 21·7)
Colombia 7·3% (0·9 to 15·6) 9·0% (1·3 to 18·2) 12·5% (1·2 to 23·9) 13·0% (1·3 to 24·8) 11·7% (2·8 to 21·0)
Dominica 4·0% (1·7 to 16·6) 5·0% (2·7 to 19·9) 9·0% (4·2 to 26·1) 7·2% (4·2 to 27·5) 6·5% (5·3 to 23·0)
Dominican Republic 9·9% (1·7 to 16·6) 12·3% (2·7 to 19·9) 16·4% (4·2 to 26·1) 17·8% (4·2 to 27·5) 16·0% (5·3 to 23·0)
Ecuador 7·1% (1·0 to 14·6) 8·7% (1·5 to 17·2) 12·6% (1·5 to 23·7) 12·6% (2·1 to 23·5) 11·4% (3·5 to 19·7)
Guatemala 2·7% (–0·3 to 6·5) 3·3% (–0·5 to 7·8) 4·4% (–1·2 to 10·1) 4·8% (–1·1 to 10·6) 4·3% (–0·3 to 9·2)
Jamaica 7·9% (1·4 to 16·1) 9·8% (2·2 to 18·5) 13·4% (2·6 to 24·8) 14·1% (2·5 to 25·5) 12·8% (4·6 to 21·6)
Mexico 6·2% (0·8 to 13·2) 7·7% (1·0 to 15·8) 10·0% (0·8 to 19·8) 11·2% (1·1 to 21·3) 10·1% (2·5 to 18·2)
Paraguay 6·8% (1·0 to 14·2) 8·5% (1·4 to 16·8) 10·9% (1·0 to 21·2) 12·2% (1·6 to 22·9) 11·0% (3·0 to 19·1)
Saint Kitts and Nevis 6·3% (2·3 to 10·5) 7·9% (3·9 to 12·2) 12·5% (5·9 to 19·5) 11·3% (6·4 to 16·5) 10·2% (8·1 to 12·4)
Uruguay 5·6% (2·1 to 9·4) 7·0% (3·5 to 10·9) 10·5% (4·8 to 16·4) 10·1% (5·6 to 14·6) 9·1% (7·2 to 11·1)
Median for region 7·1% 8·7% 12·5% 12·6% 11·4%
(Continues on next page)
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Coronary heart disease Type 2 diabetes Breast cancer Colon cancer All-cause mortality
(Continued from previous page)
North America
Canada 5·6% (0·5 to 12·2) 7·0% (0·8 to 14·4) 9·2% (0·2 to 18·6) 10·0% (0·7 to 19·5) 9·1% (1·8 to 16·6)
USA 6·7% (2·5 to 11·1) 8·3% (4·2 to 12·9) 12·4% (5·8 to 19·2) 12·0% (6·7 to 17·4) 10·8% (8·6 to 13·1)
Median for region 6·2% 7·6% 10·8% 11·0% 9·9%
Eastern Mediterranean
Iran 6·1% (2·2 to 10·2) 7·6% (3·8 to 11·8) 12·2% (5·8 to 18·9) 10·9% (6·2 to 15·8) 9·9% (7·9 to 11·9)
Iraq 9·7% (3·5 to 15·8) 12·0% (6·0 to 18·7) 14·1% (6·6 to 21·9) 17·3% (9·7 to 25·1) 15·6% (12·5 to 18·8)
Kuwait 10·7% (3·9 to 17·7) 13·2% (6·6 to 20·7) 18·8% (8·8 to 29·2) 19·1% (10·6 to 27·7) 17·2% (13·7 to 20·8)
Lebanon 7·8% (2·9 to 12·9) 9·6% (4·7 to 14·9) 10·9% (5·1 to 16·9) 13·8% (7·6 to 20·0) 12·5% (9·9 to 15·1)
Libya 7·6% (2·8 to 12·5) 9·4% (4·7 to 14·7) 14·2% (6·6 to 21·9) 13·6% (7·4 to 19·5) 12·2% (9·7 to 14·8)
Pakistan 6·7% (1·0 to 14·0) 8·3% (1·4 to 16·3) 12·5% (1·9 to 23·6) 12·0% (1·6 to 22·0) 10·8% (3·2 to 18·8)
Saudi Arabia 11·4% (4·2 to 18·8) 14·1% (7·1 to 21·9) 19·9% (9·2 to 30·6) 20·4% (11·3 to 29·3) 18·4% (14·7 to 22·1)
Tunisia 5·9% (0·7 to 12·6) 7·4% (1·0 to 15·0) 10·5% (1·0 to 20·2) 10·6% (1·0 to 20·3) 9·6% (2·4 to 17·1)
United Arab Emirates 10·3% (2·6 to 19·9) 12·8% (3·8 to 23·6) 18·0% (5·9 to 30·9) 18·5% (5·2 to 31·7) 16·7% (7·3 to 26·2)
Median for region 7·8% 9·6% 14·1% 13·8% 12·5%
Europe
Austria 5·8% (0·6 to 12·1) 7·1% (1·0 to 14·5) 10·2% (0·8 to 20·1) 10·3% (1·1 to 19·4) 9·3% (2·3 to 16·5)
Belgium 7·1% (1·2 to 14·7) 8·8% (1·9 to 17·0) 11·7% (2·0 to 21·5) 12·6% (2·1 to 23·1) 11·4% (3·7 to 19·5)
Bosnia and Herzegovina 5·6% (0·4 to 12·1) 6·9% (0·8 to 14·1) 9·6% (0·4 to 19·2) 9·9% (0·7 to 19·4) 9·0% (1·8 to 16·5)
Bulgaria 4·4% (0·1 to 9·9) 5·5% (0·1 to 11·7) 7·5% (–0·4 to 15·6) 7·9% (–0·1 to 16·1) 7·2% (0·9 to 13·6)
Croatia 3·9% (0·0 to 8·9) 4·8% (–0·1 to 10·6) 5·5% (–0·6 to 11·6) 7·0% (–0·5 to 14·3) 6·3% (0·5 to 12·4)
Cyprus 9·2% (2·0 to 17·9) 11·4% (3·0 to 21·0) 16·3% (4·2 to 28·8) 16·4% (4·3 to 28·8) 14·8% (6·2 to 24·1)
Czech Republic 4·1% (0·3 to 9·3) 5·1% (0·2 to 10·9) 5·8% (–0·4 to 12·3) 7·4% (0·0 to 14·8) 6·7% (0·9 to 12·6)
Denmark 5·8% (0·6 to 12·4) 7·2% (0·8 to 14·7) 9·2% (0·2 to 18·4) 10·4% (1·0 to 19·9) 9·4% (2·2 to 17·1)
Estonia 2·9% (–0·2 to 6·9) 3·5% (–0·4 to 8·1) 4·9% (–0·9 to 10·9) 5·1% (–0·9 to 11·2) 4·6% (–0·2 to 9·4)
Finland 6·3% (0·8 to 13·2) 7·8% (1·3 to 15·6) 9·1% (0·2 to 18·4) 11·2% (1·1 to 21·2) 10·1% (2·6 to 17·8)
France 5·4% (1·9 to 8·9) 6·7% (3·3 to 10·3) 9·7% (4·6 to 15·1) 9·6% (5·4 to 13·8) 8·7% (6·9 to 10·5)
Georgia 3·7% (1·3 to 6·2) 4·6% (2·3 to 7·1) 6·1% (2·8 to 9·5) 6·6% (3·6 to 9·6) 6·0% (4·7 to 7·2)
Germany 4·6% (0·1 to 10·4) 5·7% (0·2 to 12·4) 7·4% (–0·3 to 15·5) 8·3% (–0·3 to 16·7) 7·5% (0·9 to 14·5)
Greece 2·6% (–0·2 to 6·2) 3·2% (–0·4 to 7·4) 3·8% (–1·1 to 8·7) 4·6% (–0·9 to 10·1) 4·2% (–0·2 to 8·7)
Hungary 4·3% (0·1 to 9·5) 5·3% (0·0 to 11·4) 6·7% (–0·2 to 13·7) 7·7% (–0·2 to 15·6) 6·9% (0·7 to 13·2)
Ireland 8·8% (2·0 to 17·4) 10·9% (2·9 to 20·2) 15·2% (3·5 to 27·3) 15·7% (4·1 to 27·6) 14·2% (6·0 to 22·9)
Italy 9·1% (1·9 to 18·0) 11·2% (3·0 to 20·9) 15·6% (4·2 to 28·0) 16·2% (3·9 to 28·1) 14·6% (5·8 to 23·7)
Kazakhstan 5·2% (0·4 to 11·5) 6·5% (0·6 to 13·4) 8·1% (–0·2 to 16·3) 9·3% (0·5 to 18·4) 8·4% (1·5 to 15·6)
Latvia 5·3% (0·3 to 11·5) 6·6% (0·5 to 13·6) 9·4% (0·1 to 18·7) 9·5% (0·2 to 18·6) 8·5% (1·4 to 15·8)
Lithuania 3·7% (1·3 to 6·3) 4·6% (2·3 to 7·2) 6·5% (2·9 to 10·1) 6·7% (3·7 to 9·8) 6·0% (4·7 to 7·5)
Luxembourg 7·9% (1·3 to 16·0) 9·8% (1·9 to 19·1) 11·9% (1·2 to 23·0) 14·1% (2·6 to 25·8) 12·7% (4·2 to 21·8)
Malta 11·9% (3·3 to 22·3) 14·7% (5·3 to 26·0) 19·1% (6·0 to 32·4) 21·3% (7·5 to 35·3) 19·2% (9·8 to 28·9)
Netherlands 3·0% (–0·1 to 7·1) 3·7% (–0·3 to 8·3) 4·0% (–1·1 to 9·2) 5·4% (–0·6 to 11·4) 4·9% (0·0 to 9·8)
Norway 7·3% (1·2 to 15·3) 9·1% (1·7 to 17·9) 11·7% (1·5 to 22·2) 13·1% (2·2 to 24·1) 11·8% (3·5 to 20·2)
Poland 4·6% (0·2 to 10·4) 5·7% (0·3 to 12·0) 8·2% (–0·2 to 17·0) 8·2% (–0·1 to 16·4) 7·4% (1·0 to 13·9)
Portugal 8·4% (1·7 to 17·3) 10·5% (2·6 to 20·2) 14·2% (3·1 to 25·9) 15·1% (3·6 to 27·0) 13·6% (5·2 to 22·6)
Romania 6·4% (0·7 to 13·6) 7·9% (1·2 to 15·8) 12·0% (1·2 to 23·2) 11·4% (1·3 to 21·9) 10·3% (2·6 to 18·4)
Russia 3·4% (–0·1 to 8·1) 4·3% (–0·2 to 9·5) 4·9% (–0·9 to 10·7) 6·2% (–0·6 to 13·1) 5·6% (0·2 to 11·0)
Serbia 11·3% (3·1 to 20·9) 14·0% (4·7 to 24·6) 19·1% (6·9 to 32·3) 20·2% (7·0 to 33·5) 18·2% (9·4 to 27·6)
Slovakia 3·7% (0·1 to 8·5) 4·6% (0·0 to 9·9) 5·5% (–0·9 to 12·1) 6·6% (–0·3 to 13·7) 5·9% (0·5 to 11·5)
Slovenia 5·0% (0·3 to 11·1) 6·2% (0·4 to 12·9) 8·8% (0·2 to 17·5) 8·9% (0·0 to 17·6) 8·0% (1·2 to 15·2)
Spain 8·3% (1·7 to 16·7) 10·3% (2·5 to 19·5) 13·8% (2·6 to 25·5) 14·9% (3·1 to 26·6) 13·4% (4·9 to 22·4)
Sweden 7·3% (1·2 to 15·1) 9·1% (1·9 to 17·4) 11·5% (1·6 to 21·7) 13·1% (2·1 to 24·1) 11·8% (3·8 to 20·2)
Turkey 9·3% (2·1 to 18·3) 11·5% (3·2 to 21·0) 16·3% (4·0 to 28·9) 16·6% (4·2 to 29·0) 15·0% (6·2 to 23·9)
(Continues on next page)
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with no leisure activity, adjusted for poten tial confounders, 
was 0·86 (95% CI 0·77–0·96). With increasing energy 
expenditure, cor onary heart disease incidence fell further, 
in a curvilinear fashion. For this report, we used the RR 
corresponding to an activity level that met minimum 
present rec ommendations (0·86). Taking the inverse of 
this number to obtain the adjusted RR for physical 
inactivity yielded 1·16 (95% CI 1·04–1·30). Although these 
data are from only North America and Europe (ie, studies 
with suﬃ  cient infor mation to investi gate dose response), 
they are congruent with ﬁ ndings from the INTERHEART 
study17 under taken in 52 countries world wide, in which the 
adjusted odds ratio for myo cardial infarction associated 
with physical inactivity was identical (1·16, 95% CI 
1·03–1·32). We did a parallel meta-analysis to obtain the 
corresponding pooled un adjusted RR (ie, pooling crude 
and age-adjusted RRs), which was 1·33 (95% CI 1·18–1·49; 
appendix). Crude RRs were avail able for only four studies 
and pooling of these yielded a value of 1·54 (95% CI 
1·25–1·92); thus, the pooled unadjusted RR is conservative.
Coronary heart disease Type 2 diabetes Breast cancer Colon cancer All-cause mortality
(Continued from previous page)
Ukraine 3·1% (–0·2 to 7·3) 3·8% (–0·4 to 8·5) 4·3% (–0·8 to 9·3) 5·4% (–0·8 to 11·6) 4·9% (0·0 to 10·1)
UK 10·5% (4·0 to 17·3) 13·0% (6·4 to 20·2) 17·9% (8·5 to 27·8) 18·7% (10·5 to 27·1) 16·9% (13·6 to 20·3)
Median for region 5·5% 6·8% 9·3% 9·8% 8·8%
Southeast Asia
Bangladesh 0·8% (0·3 to 1·3) 1·0% (0·5 to 1·5) 1·7% (0·8 to 2·7) 1·4% (0·8 to 2·0) 1·3% (1·0 to 1·5)
Bhutan 8·7% (1·8 to 17·3) 10·7% (2·6 to 20·3) 16·6% (4·2 to 29·0) 15·5% (3·8 to 27·6) 14·0% (5·3 to 22·8)
Burma 2·1% (0·8 to 3·5) 2·6% (1·3 to 4·1) 3·9% (1·9 to 6·1) 3·8% (2·1 to 5·4) 3·4% (2·7 to 4·1)
India 2·6% (1·0 to 4·2) 3·2% (1·6 to 5·0) 4·8% (2·3 to 7·4) 4·6% (2·6 to 6·6) 4·2% (3·3 to 5·0)
Indonesia 4·9% (1·8 to 8·2) 6·1% (3·0 to 9·5) 7·3% (3·3 to 11·5) 8·8% (4·9 to 12·8) 8·0% (6·3 to 9·7)
Maldives 6·5% (0·7 to 13·9) 8·0% (1·0 to 16·1) 10·8% (0·5 to 21·4) 11·5% (1·0 to 22·1) 10·4% (2·6 to 18·5)
Nepal 2·6% (–0·3 to 6·2) 3·2% (–0·4 to 7·4) 4·4% (–1·0 to 10·1) 4·6% (–0·8 to 10·2) 4·1% (–0·2 to 8·7)
Sri Lanka 4·3% (1·6 to 7·1) 5·3% (2·7 to 8·3) 8·7% (4·2 to 13·5) 7·7% (4·2 to 11·1) 6·9% (5·5 to 8·3)
Thailand 3·2% (1·2 to 5·2) 3·9% (2·0 to 6·1) 5·6% (2·5 to 8·7) 5·7% (3·2 to 8·2) 5·1% (4·1 to 6·2)
Median for region 3·2% 3·9% 5·6% 5·7% 5·1%
Western Paciﬁ c
Australia 6·3% (0·8 to 13·1) 7·8% (1·0 to 15·4) 10·4% (0·9 to 20·2) 11·2% (1·4 to 21·2) 10·1% (2·8 to 18·0)
Cambodia 1·9% (0·7 to 3·1) 2·3% (1·1 to 3·6) 2·9% (1·3 to 4·5) 3·3% (1·8 to 4·8) 3·0% (2·4 to 3·6)
China 5·1% (1·9 to 8·5) 6·4% (3·2 to 9·8) 8·4% (4·0 to 13·0) 9·2% (5·2 to 13·1) 8·3% (6·6 to 10·0)
Cook Islands 11·9% (4·4 to 19·7) 14·8% (7·5 to 23·4) 19·1% (9·0 to 29·8) 21·3% (11·8 to 30·9) 19·2% (15·3 to 23·1)
Federated States of Micronesia 11·0% (4·1 to 18·3) 13·6% (6·8 to 21·1) 19·4% (9·1 to 30·5) 19·6% (11·0 to 28·6) 17·7% (14·1 to 21·3)
Japan 10·0% (2·4 to 19·0) 12·3% (3·6 to 22·5) 16·1% (3·9 to 29·1) 17·8% (5·0 to 30·9) 16·1% (7·2 to 25·4)
Kiribati 7·7% (2·7 to 12·8) 9·6% (4·8 to 15·0) 14·3% (6·9 to 22·3) 13·8% (7·7 to 20·0) 12·5% (9·8 to 15·1)
Laos 3·1% (–0·2 to 7·5) 3·9% (–0·4 to 8·7) 5·5% (–1·0 to 12·1) 5·6% (–0·8 to 12·0) 5·0% (–0·1 to 10·3)
Malaysia 10·2% (3·8 to 16·9) 12·6% (6·3 to 19·6) 17·1% (8·0 to 26·6) 18·2% (10·2 to 26·5) 16·4% (13·0 to 19·7)
Marshall Islands 8·2% (3·0 to 13·7) 10·2% (5·1 to 15·7) 14·5% (6·9 to 22·5) 14·7% (8·1 to 21·2) 13·2% (10·6 to 16·0)
Mongolia 1·6% (0·6 to 2·6) 1·9% (1·0 to 3·0) 2·5% (1·1 to 3·9) 2·8% (1·5 to 4·0) 2·5% (2·0 to 3·0)
Nauru 7·7% (2·9 to 12·9) 9·5% (4·8 to 14·8) 13·0% (6·2 to 20·3) 13·8% (7·6 to 19·8) 12·4% (9·8 to 14·9)
New Zealand 7·9% (2·9 to 13·1) 9·8% (4·9 to 15·2) 13·1% (6·2 to 20·3) 14·1% (7·9 to 20·3) 12·7% (10·2 to 15·4)
Papua New Guinea 3·2% (1·2 to 5·3) 4·0% (1·9 to 6·2) 5·6% (2·5 to 8·8) 5·7% (3·1 to 8·3) 5·2% (4·1 to 6·3)
Philippines 3·9% (–0·1 to 9·0) 4·9% (–0·1 to 10·7) 6·8% (–0·7 to 14·7) 7·0% (–0·5 to 14·4) 6·3% (0·4 to 12·4)
Samoa 8·5% (3·1 to 14·1) 10·5% (5·3 to 16·4) 17·0% (8·1 to 26·7) 15·1% (8·5 to 21·8) 13·6% (10·9 to 16·4)
Solomon Islands 7·2% (2·7 to 11·9) 9·0% (4·5 to 14·0) 12·9% (6·1 to 20·2) 12·9% (7·1 to 18·8) 11·7% (9·2 to 14·0)
Tonga 6·9% (2·5 to 11·5) 8·6% (4·2 to 13·4) 13·5% (6·4 to 21·1) 12·4% (6·8 to 18·0) 11·2% (8·8 to 13·6)
Vietnam 2·5% (–0·2 to 6·2) 3·1% (–0·4 to 7·3) 4·1% (–1·1 to 9·4) 4·5% (–0·8 to 9·8) 4·1% (–0·2 to 8·4)
Median for region 7·2% 9·0% 13·0% 12·9% 11·7%
Overall
Median 5·8% 7·2% 10·1% 10·4% 9·4%
Data are PAF (95% CI). PAF=population attributable fraction. *PAFs calculated with unadjusted relative risks are shown in the appendix.
Table 2: Estimated PAFs, calculated with adjusted relative risks,* for coronary heart disease, type 2 diabetes, breast cancer, colon cancer, and all-cause 
mortality associated with physical inactivity, by WHO region and country
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Gain in life expectancy (years)
Africa
Algeria 0·79 (0·62 to 0·96)
Benin 0·19 (0·15 to 0·24)
Botswana 0·81 (0·64 to 0·99)
Burkina Faso 0·31 (–0·01 to 0·66)
Cameroon 0·85 (0·26 to 1·49)
Cape Verde 0·46 (0·35 to 0·56)
Chad 0·46 (0·03 to 0·93)
Comoros 0·17 (–0·04 to 0·40)
Congo (Brazzaville) 1·06 (0·35 to 1·87)
CÔte d’Ivoire 0·72 (0·16 to 1·37)
Democratic Republic of the Congo 0·89 (0·70 to 1·09)
Eritrea 0·89 (0·70 to 1·08)
Ethiopia 0·43 (0·02 to 0·89)
Gabon 0·81 (0·15 to 1·55)
Ghana 0·40 (0·32 to 0·49)
Guinea 0·25 (–0·01 to 0·53)
Kenya 0·37 (–0·02 to 0·79)
Madagascar 0·52 (0·41 to 0·63)
Malawi 0·21 (0·17 to 0·26)
Mali 0·40 (0·14 to 0·81)
Mauritania 0·95 (0·35 to 1·60)
Mauritius 0·90 (0·22 to 1·62)
Mozambique 0·14 (0·11 to 0·17)
Namibia 1·45 (0·62 to 2·39)
Niger 0·57 (0·45 to 0·69)
São Tomé and PrÍncipe 0·36 (0·28 to 0·44)
Senegal 0·49 (0·04 to 0·97)
Seychelles 0·51 (0·40 to 0·63)
Sierra Leone 0·38 (0·30 to 0·46)
South Africa 1·26 (0·99 to 1·53)
Swaziland 1·56 (0·76 to 2·45)
The Gambia 0·52 (0·41 to 0·63)
Zambia 0·36 (–0·02 to 0·77)
Zimbabwe 0·56 (0·05 to 1·13)
Median for region 0·51
Latin America and Caribbean
Argentina 1·39 (0·71 to 2·14)
Barbados 0·91 (0·72 to 1·11)
Brazil 1·08 (0·38 to 1·81)
Colombia 0·82 (0·19 to 1·50)
Dominica 0·51 (0·41 to 1·86)
Dominican Republic 1·28 (0·41 to 1·87)
Ecuador 0·80 (0·24 to 1·41)
Guatemala 0·35 (–0·02 to 0·74)
Jamaica 1·01 (0·36 to 1·74)
Mexico 0·76 (0·18 to 1·40)
Paraguay 0·85 (0·23 to 1·51)
Saint Kitts and Nevis 0·77 (0·61 to 0·95)
Uruguay 0·70 (0·55 to 0·85)
Median for region 0·82
(Continues in next column)
Gain in life expectancy (years) 
(Continued from previous column)
North America
Canada 0·55 (0·11 to 1·02)
USA 0·78 (0·62 to 0·94)
Median for region 0·66
Eastern Mediterranean
Iran 0·71 (0·57 to 0·87)
Iraq 1·30 (1·03 to 1·59)
Kuwait 1·12 (0·89 to 1·37)
Lebanon 0·95 (0·75 to 1·16)
Libya 0·93 (0·77 to 1·18)
Pakistan 0·85 (0·25 to 1·52)
Saudi Arabia 1·51 (1·19 to 1·84)
Tunisia 0·64 (0·16 to 1·16)
United Arab Emirates 1·11 (0·48 to 1·78)
Median for region 0·95
Europe
Austria 0·58 (0·14 to 1·03)
Belgium 0·73 (0·23 to 1·26)
Bosnia and Herzegovina 0·62 (0·12 to 1·16)
Bulgaria 0·58 (0·07 to 1·11)
Croatia 0·45 (0·04 to 0·91)
Cyprus 0·80 (0·33 to 1·33)
Czech Republic 0·48 (0·06 to 0·92)
Denmark 0·64 (0·15 to 1·19)
Estonia 0·38 (–0·02 to 0·78)
Finland 0·66 (0·17 to 1·17)
France 0·55 (0·44 to 0·67)
Georgia 0·52 (0·41 to 0·63)
Germany 0·47 (0·06 to 0·92)
Greece 0·23 (–0·01 to 0·49)
Hungary 0·61 (0·06 to 1·18)
Ireland 0·87 (0·36 to 1·42)
Italy 0·80 (0·31 to 1·32)
Kazakhstan 0·79 (0·14 to 1·50)
Latvia 0·77 (0·12 to 1·46)
Lithuania 0·53 (0·41 to 0·65)
Luxembourg 0·83 (0·27 to 1·45)
Malta 1·12 (0·56 to 1·71)
Netherlands 0·29 (0·00 to 0·59)
Norway 0·68 (0·20 to 1·18)
Poland 0·60 (0·08 to 1·14)
Portugal 0·86 (0·33 to 1·45)
Romania 0·87 (0·21 to 1·58)
Russia 0·52 (0·02 to 1·05)
Serbia 1·50 (1·02 to 2·33)
Slovakia 0·46 (0·04 to 0·92)
Slovenia 0·54 (0·08 to 1·05)
Spain 0·78 (0·28 to 1·32)
Sweden 0·67 (0·22 to 1·16)
Turkey 1·06 (0·43 to 1·74)
(Continues in next column)
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For the association of type 2 diabetes incidence with 
physical activity, Jeon and co-workers11 reported a 
pooled RR of 0·83 (95% CI 0·76–0·90), adjusted for 
several confounders including body-mass index (BMI). 
Taking the inverse to obtain the adjusted RR for 
inactivity, we calculated an RR of 1·20 (95% CI 
1·10–1·33). We calculated the corresponding, pooled 
unadjusted RR, which was 1·63 (95% CI 1·27–2·11; 
appendix). This mag nitude of risk increase was similar 
to that pooling only the crude RRs, which yielded 1·58 
(95% CI 1·11–2·26).
We used the primary papers in the qualitative review by 
Friedenreich and colleagues15 to undertake a meta-
analysis of the pooled adjusted and unadjusted RRs 
for breast cancer incidence (appendix). The adjusted RR 
for physical inactivity, including adjustment for BMI, 
was 1·33 (95% CI 1·26–1·42). This result was little 
diﬀ erent from the unadjusted RR of 1·34 (95% CI 
1·25–1·43; similar to that pooling only crude RRs, 
yielding 1·35, 95% CI 1·26–1·45).
For the association of colon cancer incidence and 
physical activity, Wolin and colleagues12 reported a pooled 
adjusted RR of 0·76 (95% CI 0·72–0·81). Taking the 
inverse of these results gave an adjusted RR of 1·32 
(95% CI 1·23–1·39) for inactivity. Our calculation of the 
pooled unadjusted RR for colon cancer was 1·38 (95% CI 
1·31–1·45; appendix); the pooled crude RR was similar 
(1·37, 95% CI 1·29–1·46).
Lollgen and colleagues13 reported a meta-analysis of 
RRs for all-cause mortality associated with moderate and 
high levels of physical activity, qualitatively deﬁ ned. 
Investigators reported separate estimates for studies in 
which participants were classiﬁ ed into three, four, or ﬁ ve 
levels of activity. The adjusted RRs for moderate levels 
compared with a low level ranged from 0·53 to 0·78; for 
high levels, from 0·52 to 0·80. We used their primary 
papers to do a meta-analysis to obtain one pooled RR that 
compared low with moderate physical activity—ie, a 
conservative estimate of the eﬀ ect of inactivity. Our 
pooled adjusted RR was 1·28 (95% CI 1·21–1·36), 
whereas the pooled unadjusted RR was 1·47 (95% CI 
1·38–1·57) and similar to the pooled crude RR of 
1·46 (95% CI 1·34–1·60; appendix).
For coronary heart disease, median PAFs associated 
with physical inactivity, calculated with adjusted RRs, 
ranged from 3·2% (in southeast Asia) to 7·8% (in  the 
eastern Mediterranean region), with an overall median of 
6% (tables 1, 2). These results suggest that 6% of the 
burden of disease worldwide due to coronary heart 
disease can be eliminated, if all inactive people become 
active. The burden of disease was 7% for type 2 diabetes 
(ranging from 3·9% to 9·6%), 10% (5·6–14·1) for breast 
cancer, and 10% (5·7–13·8) for colon cancer.
Removal of physical inactivity had the largest eﬀ ect on 
colon cancer, and the smallest on coronary heart disease, 
in terms of percentage reduction. However, with respect 
to the number of cases that can potentially be averted, 
coronary heart disease would have a far larger eﬀ ect than 
would colon cancer because of its higher incidence. 
Although the worldwide incidence of coronary heart 
disease is not readily available, deaths from coronary 
heart disease can be viewed against colorectal cancer 
deaths to provide some perspective; in 2008, 7·25 million 
people worldwide died from coronary heart disease 
versus 647 000 from colorectal cancer.18 Applying the 
median PAFs, we estimated that 15 000 deaths from 
Gain in life expectancy (years) 
(Continued from previous column)
Ukraine 0·46 (0·00 to 0·97)
UK 1·07 (0·85 to 1·29)
Median for region 0·63
Southeast Asia
Bangladesh 0·10 (0·08 to 0·12)
Bhutan 1·15 (0·42 to 1·95)
Burma 0·27 (0·22 to 0·33)
India 0·34 (0·27 to 0·41)
Indonesia 0·65 (0·51 to 0·80)
Maldives 0·75 (0·18 to 1·37)
Nepal 0·33 (–0·02 to 0·71)
Sri Lanka 0·51 (0·40 to 0·61)
Thailand 0·41 (0·32 to 0·49)
Median for region 0·41
Western Paciﬁ c
Australia 0·56 (0·15 to 1·00)
Cambodia 0·24 (0·19 to 0·29)
China 0·61 (0·48 to 0·73)
Cook Islands 1·57 (1·24 to 1·91)
Federated States of Micronesia 1·45 (1·14 to 1·77)
Japan 0·91 (0·40 to 1·46)
Kiribati 1·27 (0·99 to 1·55)
Laos 0·43 (–0·01 to 0·90)
Malaysia 1·35 (1·06 to 1·65)
Marshall Islands 1·33 (1·04 to 1·63)
Mongolia 0·24 (0·19 to 0·29)
Nauru 1·21 (0·95 to 1·47)
New Zealand 0·76 (0·61 to 0·93)
Papua New Guinea 0·43 (0·34 to 0·52)
Philippines 0·52 (0·03 to 1·04)
Samoa 1·17 (0·92 to 1·42)
Solomon Islands 0·90 (0·70 to 1·09)
Tonga 1·03 (0·80 to 1·26)
Vietnam 0·31 (–0·01 to 0·64)
Median for region 0·90
Overall
Median 0·68
Data in parentheses are 95% CI. Uncertainty interval calculated on the basis of the 
lower and upper bounds of the 95% CI of the adjusted population attributable 
fraction for all-cause mortality.
Table 3: Estimated gains in life expectancy if physical inactivity were 
eliminated, by WHO region and country
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coronary heart disease in Africa could have been averted 
in 2008 by removal of physical inactivity. 60 000 could 
have been avoided in the Americas, 44 000 in the eastern 
Mediterranean region, 121 000 in Europe, 59 000 in 
southeast Asia, and 100 000 in the western Paciﬁ c region. 
With respect to deaths from breast cancer, 3000 could 
have been averted in Africa, 11 000 in the Americas, 
4000 in the eastern Mediterranean, 14 000 in Europe, 
5000 in southeast Asia, and 10 000 in the western Paciﬁ c; 
for deaths from colorectal cancer, these numbers were 
1000, 14 000, 2000, 24 000, 4000, and 24 000, respectively.
For all-cause mortality, the overall median PAF was 9%. 
Applying this ﬁ gure to the 57 million deaths worldwide in 
2008,18 we estimated that more than 5·3 million deaths 
(ranging from 525 000 in the eastern Mediterranean to 
1·5 million in the western Paciﬁ c region) could be averted 
every year if all inactive people become active. Because 
physical inactivity is unlikely to be completely eliminated, 
we further estimated poten tial deaths averted when 
assuming a decrease of inactivity prevalence by 10% or 
25% with eﬀ ective public health interventions, instead of 
100% (elimin ation). These alternate scenarios resulted in 
more than 533 000 and 1·3 million deaths potentially 
avoided worldwide each year.
Using an alternate classiﬁ cation of countries by income 
(data not shown), we calculated median PAFs for all-cause 
mortality of 4% for countries with low incomes, 8% for 
lower-middle incomes, 10% for upper-middle incomes, 
and 11% for high incomes (with number of deaths averted 
ranging from 409 000 in countries with low incomes to 
2·5 million in those with lower-middle incomes). This 
analysis yielded estimated numbers of deaths potentially 
averted in 2008 from coronary heart disease of 15 000, 
184 000, 96 000, and 98 000; from breast cancer of 2000, 
16 000, 10 000, and 20 000; and from colorectal cancer of 
1000, 19 000, 13 000, and 37 000, respectively.
We estimated that the median years of life potentially 
gained worldwide with elimination of physical inactivity 
was 0·68 years (ranging from 0·41 years in southeast 
Asia to 0·95 years in the eastern Mediterranean region; 
table 3, ﬁ gure). When we classiﬁ ed countries by income, 
the median gains were 0·37 years for countries with low 
incomes, 0·65 for lower-middle incomes, 0·80 for upper-
middle incomes, and 0·68 years for high incomes. In a 
sensitivity analysis that decreased age-speciﬁ c death 
rates by the PAF for all ages 40 years or older (instead of 
only ages 40–79 years), the new estimate of years 
gained worldwide increased to a median of 0·92 years 
(range 0·49–1·25).
Finally, we used an example to illustrate gains under 
less stringent assumptions. A recent study of Taiwanese 
people aged 20 years and older comparing most with 
least active groups reported an RR for all-cause mortality 
of 1·35.19 Applying this RR to China for people aged 
20 years and older, we calculated a PAF of 9·8% and gain 
in life expectancy of 1·03 years, versus 8·3% and 
0·61 years obtained under the standard assumptions of 
tables 2 and 3.
Discussion
Worldwide, we estimated that physical inactivity causes 
6–10% of the major non-communicable diseases of 
coronary heart disease, type 2 diabetes, and breast and 
colon cancers. Furthermore, this unhealthy behaviour 
causes 9% of premature mortality, or more than 5·3 of 
the 57 million deaths in 2008.18 With elimination of 
physical inactivity, life expectancy of the world’s popu-
lation might be expected to increase by 0·68 years. 
These ﬁ ndings make inactivity similar to the established 
risk factors of smoking and obesity. The added years of 
life need to be interpreted correctly: they seem low 
because they represent gains in the whole population 
(including inactive and active people), rather than in 
inactive people who become active. Because all the gain 
accrues to people who move from inactive to active, the 
increase in life expectancy in the inactive group alone is 
Figure: Estimated gains in life expectancy worldwide with elimination of physical inactivity
≥1·00
0·75–0·99
0·50–0·74
0·25–0·49
<0·25
No data
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greater. For perspective, other research done in the USA 
estimated that inactive people would gain 1·3–3·7 years 
from age 50 years by becoming active.20,21 In an east 
Asian population, life expectancy from age 30 years in 
active people was 2·6–4·2 years greater than that in 
inactive people.19
How does physical inactivity compare with other 
risk factors for poor health? Although risk factors are 
classiﬁ ed on diﬀ erent scales (thus, the proportion at risk 
varies across risk factors), it is nonetheless informative to 
look at two established risk factors targeted for govern-
ment action worldwide: smoking and obesity. Smoking 
was estimated to cause about 5 million deaths world-
wide in 2000.22 The proportion of deaths attrib utable to 
smoking in China, one of the top ﬁ ve cigarette-
consuming countries, has been estimated at 3·1% for 
women and 12·9% for men.23 By elimination of smoking, 
life expectancy at age 50 years was estimated to increase 
by 2·3–2·5 years in the US population and 1·1–2·2 years 
in the populations of nine other high-income countries.24 
At an individual level, Beijing never-smokers aged 
55 years and older had a life expectancy 4·2–8·8 years 
longer than that of present smokers.25 As for obesity, if all 
obese people in the USA were to attain normal weight, 
life expectancy in the population was estimated to 
increase by 0·7–1·1 years at birth in one analysis26 and 
0·5–0·7 years at age 50 years in another.24 Thus, physical 
inactivity seems to have an eﬀ ect similar to that of 
smoking or obesity.
The present analysis updates information from a 
2004 WHO report27 and additionally estimates added 
years of life expectancy in the population. In the WHO 
report, because of unavailability of data needed for the 
preferred PAF formula, the incorrect formula (formula 1) 
was used. Their PAFs ranged from 10% for breast cancer 
to 22% for coronary heart disease—similar to the present 
estimate for breast cancer, but larger for coronary heart 
disease. In part, this diﬀ erence is because the RR of 
breast cancer for physical inactivity is not confounded by 
other variables (unadjusted RR 1·34, adjusted RR 1·33), 
whereas that for coronary heart disease is (unadjusted 
RR 1·33, adjusted RR 1·16). Further, we conservatively 
used a pooled RR for coronary heart disease that com-
pared physical inactivity with the minimum recom-
mended activity level using recently published data,10 
whereas WHO used data available at the time of their 
analysis that compared extreme activity categories, 
yielding RRs of larger magnitude.
Our estimates are likely to be very conservative. First, 
the RRs were almost always based on self-reported 
physical activity levels,28 which are imprecise. In pro-
spective studies in which self-reports cannot be biased by 
the outcomes studied (since they have not yet occurred at 
the time of reporting), random reporting errors result in 
underestimation of the RRs. Some studies of physical 
ﬁ tness—a related measure to physical activity that is 
more objectively measured—show stronger magnitudes 
of association with non-communicable diseases29 (which 
also might reﬂ ect inherited physiological and metabolic 
characteristics related to both ﬁ tness and a favourable 
risk proﬁ le). Second, the pooled RRs were derived from 
maximally adjusted RRs in the primary studies. Often, 
these RRs were adjusted for characteristics such as blood 
pressure, lipid proﬁ le, and glucose or insulin sensitivity. 
These could be overadjustments, since physical activity 
reduces risk of coronary heart disease and premature 
mortality partly through beneﬁ cial eﬀ ects on these 
variables (a recent analysis suggested an attenuation of 
about 10% in the RR10). For type 2 diabetes, we used RRs 
adjusted for BMI—also conservative, since physical 
activity plays an important part in weight management.3 
Third, we used the same RR to calculate PAFs for all 
countries, based on data mainly from North America and 
Europe. Whether physical inactivity has similar eﬀ ects in 
other populations is unclear. For example, we used a 
pooled adjusted RR for coronary heart disease of 1·16; 
however, a study in India reported a larger adjusted RR 
(2·27, 95% CI 1·41–3·70).30 However, our pooled adjusted 
RR for all-cause mortality, 1·28, is similar to that of 1·25 
(95% CI 1·18–1·33) in an east Asian study, comparing 
inactive people with those meeting minimum physical 
activity recommendations.19 Fourth, we assumed physical 
activ ity to reduce all-cause mortality rates only at ages 
40–79 years. In a sensitivity analysis that extended the 
beneﬁ t to age 40 years and older, larger gains in life 
expectancy were obtained. Fifth, we used one RR instead 
of a range of RRs to reﬂ ect the dose-response relation 
between physical inactivity and risks of non-com-
municable disease because sparse data are available for 
the dose-response relation.10 In an illustrative example 
using China, we showed that applying less stringent 
assumptions increased PAF by 18% (9·8% vs 8·3%) and 
life expectancy by 69% (1·03 vs 0·61 years) compared 
with calculations made under standard assumptions.
Limitations of this study include the use of an adjustment 
factor to estimate the prevalence of physical inactivity in 
cases. This adjustment factor was mainly based on 
populations in North America and Europe, and one study 
each from China and India; how applicable this factor 
might be to other countries such as those in Africa or with 
low incomes is unclear. Also, successful interventions will 
probably increase activity levels across the board, instead 
of shifting people across a binary divide of inactive to active 
assumed in our calculations, potentially yielding greater 
beneﬁ ts. We examined only the major non-communicable 
diseases and all-cause mortality, and not other disorders 
aﬀ ected by physical inactivity (panel 1) or disability 
resulting from non-communicable diseases. Finally, not all 
physically in active people choose to be so; some might be 
physically incapable.
This summer, we will admire the breathtaking feats 
of athletes competing in the 2012 Olympic Games. 
Although only the smallest fraction of the population will 
attain these heights, the overwhelming majority of us are 
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able to be physically active at very modest levels— 
eg, 15–30 min a day of brisk walking—which bring 
substantial health beneﬁ ts.3–5,19 We must explore all 
avenues and support all eﬀ orts to reduce physical 
inactivity worldwide.
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